/ATNFW
ATNFW Stock - ETHZilla Corporation Warrant
Healthcare|Medical - PharmaceuticalsNASDAQ
$0.43-6.52%
$0.03 (-6.52%) • Aug 15
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.47
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ATNFW
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.43 – $0.43
TARGET (TP)$0.49
STOP LOSS$0.40
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.41
52W High$0.44
52W Low$0.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-58,277 | $-106,000 | $-109,000 | $-116,000 | $-125,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-6,325,000 | $-13,477,000 | $-17,898,000 | $-15,641,000 | $-5,648,000 |
| Net Income | $-6,168,000 | $-19,935,000 | $-38,726,259,000,000 | $-20,324,648,000,000 | $-12,006,760,000,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-6.74 | $-52.59 | $-1966837.38 | $-2463175.70 | $-251329412.01 |
Company Overview
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ATNFWBeat Rate
100%
Last 6 quarters
Avg Surprise
+63.3%
EPS vs Estimate
Beats / Misses
6/0
Last 12 quarters
Latest EPS
$-17.45
Q4 2025
EPS Surprise History
Q1 24
+89.9%
$-2.29vs$-22.80
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | — | $-17.45 | — | — |
Q3 2025 | Jul 23, 2025 | — | $-0.30 | — | — |
Q2 2025 | May 15, 2025 | — | $-2.59 | — | — |
Q1 2025 | Mar 31, 2025 | — | $-4.67 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.85 | — | — |
Q3 2024 | Aug 12, 2024 | — | $0.01 | — | — |
Q2 2024 | May 15, 2024 | — | $-1.68 | — | — |
Q1 2024 | Mar 23, 2024 | $-22.80 | $-2.29 | +89.9% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-26.60 | $-24.53 | +7.8% | ✓ BEAT |
Q3 2023 | Aug 15, 2023 | $-26.60 | $-13.37 | +49.8% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-38.00 | $-24.15 | +36.5% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-41.80 | $-1.10 | +97.4% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-38.00 | $-0.55 | +98.6% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | — | $0.09 | — | — |
Q2 2022 | May 16, 2022 | — | $0.05 | — | — |
Q1 2022 | Mar 31, 2022 | — | $0.12 | — | — |
Q4 2021 | Nov 12, 2021 | — | $0.54 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-0.75 | — | — |
Q3 2021 | Jul 17, 2021 | — | $-0.58 | — | — |
Q3 2021 | Jul 9, 2021 | — | $-0.57 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ATNFW
What is ATNFW's current stock price?
ETHZilla Corporation Warrant (ATNFW) is currently trading at $0.43 per share. The stock has moved -6.52% today.
What is the analyst price target for ATNFW?
No analyst price targets are currently available for this stock.
What sector is ETHZilla Corporation Warrant in?
ETHZilla Corporation Warrant operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the NASDAQ exchange.
What is ATNFW's market cap?
ETHZilla Corporation Warrant has a market capitalization of $0.00 billion, making it a small-cap company.
Does ATNFW pay dividends?
No, ETHZilla Corporation Warrant does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAWH
Aspira Women's Health Inc.
$0.08
Mkt Cap: $0.0B
BPTS
Biophytis S.A.
$8.22
Mkt Cap: $0.0B
EIGRQ
Eiger BioPharmaceuticals, Inc.
$8.50
Mkt Cap: $0.0B
HIND
Vyome Holdings, Inc.
$3.68
Mkt Cap: $0.0B
MDVL
MedAvail Holdings, Inc.
$1.80
Mkt Cap: $0.0B
NOVN
Novan, Inc.
$0.09
Mkt Cap: $0.0B
NTBL
Notable Labs, Ltd.
$0.25
Mkt Cap: $0.0B
PLXP
PLx Pharma Inc.
$0.09
Mkt Cap: $0.0B
PTN
Palatin Technologies, Inc.
$17.05
Mkt Cap: $0.4B
SQL
SeqLL Inc.
$6.60
Mkt Cap: $0.0B
Explore stocks similar to ATNFW for comparison